News

FDA approves combo of Opdivo plus Yervoy for advanced liver cancer
The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for ...
MPR1d
Opdivo + Yervoy Approved as First-Line Tx for Hepatocellular Carcinoma
The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...
Pharmaceutical Technology on MSN3d
BMS’ Opdivo combo approved in US for hepatocellular carcinoma
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...
Medscape3d
FDA OKs First-line Nivolumab + Ipilimumab in Advanced HCC
The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...
Healio18h
Combination immunotherapy better than single agent in head, neck cancer
Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck squamous cell carcinoma, according to results of a randomized phase 2 ...
MPR7d
Opdivo + Yervoy Approved as First-Line Tx for MSI-H/dMMR Metastatic Colorectal Cancer
The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...
CURE2d
Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC
Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...
Targeted Oncology2d
Nivolumab Plus Ipilimumab Trends Toward Prolonged OS in nccRCC
Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...